When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
![230925_postapproval](https://quibim.com/wp-content/uploads/2023/05/230925_postapproval.jpg?t=1695728638&ratio=2.1385416666667 2053w, https://quibim.com/wp-content/uploads/2023/05/230925_postapproval-1250x585.jpg?t=1695728640&ratio=2.1367521367521 1250w, https://quibim.com/wp-content/uploads/2023/05/230925_postapproval-625x292.jpg?t=1695728640&ratio=2.1404109589041 625w, https://quibim.com/wp-content/uploads/2023/05/230925_postapproval-350x164.jpg?t=1695728640&ratio=2.1341463414634 350w)
The challenge
A top-tier biopharmaceutical company had an already approved monoclonal antibody for treating axial Spondylarthritis (axSpA). The diagnosis of axSpA is based on Magnetic Resonance Imaging (MRI) and its interpretation is challenging and subjective. 16.4% of patients with Chronic Low Back Pain (CLBP) are misdiagnosed and suffer from axSpA [van Hoeven et al. Arthritis Research & Therapy (2017) 19:143]. AxSpA is diagnosed with an average delay of 7 years.
The revenue originated from the drug commercialization was unpredictable due to the variability in the radiologist’s expertise in the interpretation of sacroiliac joints MRI across hospitals.
The solution
Quibim and the biopharmaceutical company entered a strategic partnership structured in two phases: algorithm development and clinical validation with the regulatory clearance, and algorithm on-site deployment. The biopharmaceutical partner supported the collection of MRI exams for AI model training through their network of hospitals.
- Quibim’s solution will allow for an increased predictability of revenue across hospitals by standardizing a diagnostic aid for axSpA.
- Quibim’s solution will offer a systematic method for interpretation of imaging data through QP-Discovery® cloud platform that all rheumatologists and radiologists from the sites can use to analyze the MRI exams and to obtain the output of the algorithm.
- The algorithm will lead the digital transformation of the drug marketing strategy, offering the drug to the clinical specialist and an AI-based tool to diagnose the disease.
The outcome
We will design and create a new tool with an already-existing product-market fit and a unique value proposition – currently in a category with no competitors. We are now scaling the relationship with the biopharmaceutical company to other indications using an already existing algorithm implemented and cleared by us.
![Image 1 axSpA CS](https://quibim.com/wp-content/uploads/2022/11/Image-1-axSpA-CS-2500x1051.png?t=1685516984&ratio=2.3786869647954 2500w, https://quibim.com/wp-content/uploads/2022/11/Image-1-axSpA-CS-1250x525.png?t=1685516982&ratio=2.3809523809524 1250w, https://quibim.com/wp-content/uploads/2022/11/Image-1-axSpA-CS-625x263.png?t=1685516982&ratio=2.3764258555133 625w, https://quibim.com/wp-content/uploads/2022/11/Image-1-axSpA-CS-350x147.png?t=1685516981&ratio=2.3809523809524 350w)
Related case studies
-
Empowering DIPG and Neuroblastoma through advanced imaging biomarkers
Read more
-
Prognostic value of genetic alterations and 18F-FDG PET/CT imaging features in diffuse large B cell lymphoma
Read more
-
Development of CT-based radiomic model to predict 5-year progression free survival in locally advanced head and neck squamous cell carcinoma treated with definitive chemoradiation
Read more